Dr. Nader Oskooilar

Newport Beach, CA
Specialties:Psychiatry
OverviewInsuranceLocationsClinical Research

Overview

Nader Oskooilar is a Psychiatrist in Newport Beach, California. His top area of expertise is Attention Deficit Hyperactivity Disorder (ADHD).

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Psychiatry
Licenses
Psychiatry & Neurology in CA
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

1601 Dove St, Newport Beach, CA 92660
949-244-7518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine
Enrollment Status: Completed
Publish Date: June 28, 2024
Intervention Type: Drug
Study Drugs: Galcanezumab, Rimegepant
Study Phase: Phase 4
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With Attention-Deficit/Hyperactivity Disorder
Enrollment Status: Completed
Publish Date: February 13, 2024
Intervention Type: Drug
Study Drug: SPN-812
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
EMERGE: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Single Doses of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug
Study Phase: Phase 3
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers
Enrollment Status: Completed
Publish Date: November 15, 2022
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability and Efficacy of LY3002813 in Early Symptomatic Alzheimer's Disease
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Drug
Study Drug: LY3002813
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Flexible-Dose Study of the Efficacy and Safety of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
Enrollment Status: Completed
Publish Date: July 12, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist
Enrollment Status: Completed
Publish Date: March 22, 2022
Intervention Type: Drug
Study Phase: Phase 4
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Subjects Not Receiving Memantine Treatment
Enrollment Status: Completed
Publish Date: October 01, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
12 Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From A Major Depressive Disorder (MDD) Having Had- Within the Current Episode- An Inadequate Response to at Least One Medication Included in GeneSight Psychotropic
Enrollment Status: Completed
Publish Date: January 14, 2020
Intervention Type: Genetic
Study Phase: Not Applicable
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
LY2951742 Biomarker Study in Patients With Migraine
LY2951742 Biomarker Study in Patients With Migraine
Enrollment Status: Completed
Publish Date: April 09, 2019
Intervention Type: Drug
Study Phase: Early Phase 1
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)
Enrollment Status: Terminated
Publish Date: February 05, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 14 Less Clinical Trials

2 Total Publications

Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Journal: Brain : a journal of neurology
Published: December 12, 2023
Similar Doctors
Expertise in
9
conditions
Dr. Jason P. Kellogg
Psychiatry
Expertise in
9
conditions
Dr. Jason P. Kellogg
Psychiatry

Jason Kellogg MD Inc

Irvine, CA 
 (2.2 mi)
949-722-7118
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jason Kellogg is a Psychiatrist in Irvine, California. Dr. Kellogg is highly rated in 9 conditions, according to our data. His top areas of expertise are Schizophrenia, Major Depression, Seasonal Affective Disorder (SAD), and Schizoaffective Disorder.

Expertise in
13
conditions
Dr. Seyed A. Sajjadi
Psychiatry | Neurology
Expertise in
13
conditions
Dr. Seyed A. Sajjadi
Psychiatry | Neurology

Regents Of The University Of Claifornia Univ Neursciences

101 The City Dr S, 
Orange, CA 
 (8.7 mi)
714-456-7004
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Seyed Sajjadi is a Psychiatrist and a Neurologist in Orange, California. Dr. Sajjadi is highly rated in 13 conditions, according to our data. His top areas of expertise are Primary Progressive Aphasia, Cerebellar Degeneration, Alzheimer's Disease, and Frontotemporal Dementia.

Expertise in
2
conditions
Dr. Lon S. Schneider
Psychiatry
Expertise in
2
conditions
Dr. Lon S. Schneider
Psychiatry
1520 San Pablo St, Ste 1652, 
Los Angeles, CA 
 (33.6 mi)
323-442-6000
Languages Spoken:
English

Lon Schneider is a Psychiatrist in Los Angeles, California. Dr. Schneider is highly rated in 2 conditions, according to our data. His top areas of expertise are Alzheimer's Disease, Dementia, Menopause, and Vascular Dementia.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile